Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.

JC, Yang; FA, Shepherd; DW, Kim; GW, Lee; JS, Lee; GC, Chang; SS, Lee; YF, Wei; YG, Lee; G, Laus; B, Collins; F, Pisetzky; L, Horn

doi:10.1016/j.jtho.2019.02.001

Public

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.

Shared by NobleBlocks on Feb 11, 2019 • 12:00 AM UTC

Authors:

Yang JC

Shepherd FA

Kim DW

Abstract

<h4>Introduction</h4>Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI). Durvalumab is an anti-programmed death ligand 1 monoclonal antibody. The phase III open-label CAURAL trial (NCT02454933) investigated osimertinib plus durvalumab versus osimertinib monotherapy in patients wi...

Subject

EGFR

Combination

Non–small Cell Lung Cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!